-+ 0.00%
-+ 0.00%
-+ 0.00%

ARCH BIOPARTNERS RECEIVES CENTRAL IRB APPROVAL TO SUPPORT U.S. SITES IN PHASE II CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY TRIAL OF LSALT PEPTIDE

Reuters·08/31/2026 12:20:00

Please log in to view news